

# Andrew David Westwell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4869295/publications.pdf>

Version: 2024-02-01

136  
papers

5,590  
citations

101543

36  
h-index

82547

72  
g-index

156  
all docs

156  
docs citations

156  
times ranked

7123  
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. <i>Immunology</i> , 2022, 165, 250-259.	4.4	21
2	Online survey into developing a model for a legal cannabis market in the United Kingdom. <i>Drug Science, Policy and Law</i> , 2021, 7, 205032452110349.	1.3	1
3	The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 775-786.	4.1	7
4	Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 36, 127817.	2.2	2
5	Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer. <i>Molecules</i> , 2021, 26, 56.	3.8	8
6	New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12272.	4.1	7
7	Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8980.	4.1	8
8	Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer. <i>Molecules</i> , 2020, 25, 3488.	3.8	7
9	Radiosynthesis of [ <sup>18</sup> F]-Labelled Pro-Nucleotides (ProTides). <i>Molecules</i> , 2020, 25, 704.	3.8	5
10	Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells. <i>Medicinal Chemistry</i> , 2020, 17, 40-59.	1.5	7
11	The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation. <i>Frontiers in Microbiology</i> , 2019, 10, 1444.	3.5	2
12	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfonyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 1-14.	5.5	19
13	Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126721.	2.2	12
14	Using the pharmacy retail model to examine perceptions and biases of a UK population sample towards regulation of specific psychoactive drugs. <i>Drug Science, Policy and Law</i> , 2019, 5, 205032451987612.	1.3	3
15	Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 49-60.	5.5	12
16	Antischistosomal Properties of Sclareol and Its Heck-Coupled Derivatives: Design, Synthesis, Biological Evaluation, and Untargeted Metabolomics. <i>ACS Infectious Diseases</i> , 2019, 5, 1188-1199.	3.8	26
17	New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2. <i>Molecules</i> , 2019, 24, 1274.	3.8	33
18	Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances. <i>Future Medicinal Chemistry</i> , 2019, 11, 161-164.	2.3	2

#	ARTICLE	IF	CITATIONS
19	The discovery of purine-based agents targeting triple-negative breast cancer and the $\beta$ -crystallin/VEGF protein-protein interaction. <i>Medicinal Chemistry Research</i> , 2019, 28, 182-202.	2.4	5
20	A framework for the development of effective anti-metastatic agents. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 185-204.	27.6	223
21	Repurposing old carbon monoxide-releasing molecules towards the anti-angiogenic therapy of triple-negative breast cancer. <i>Oncotarget</i> , 2019, 10, 1132-1148.	1.8	15
22	Design, synthesis and anthelmintic activity of 7-keto-sempervirolo analogues. <i>European Journal of Medicinal Chemistry</i> , 2018, 152, 87-100.	5.5	40
23	The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. <i>Chemical Biology and Drug Design</i> , 2018, 91, 314-321.	3.2	8
24	Pharmacies as potential providers of harm reduction services: A preliminary online survey. <i>Drug Science, Policy and Law</i> , 2018, 4, 205032451876744.	1.3	4
25	Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity <i>in Vitro</i> and Tissue Selectivity <i>in Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1846-1858.	4.1	7
26	Antimicrobial Activities of New Indole Derivatives Containing 1,2,4-Triazole, 1,3,4-Thiadiazole and Carbothioamide. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2018, 15, 291-297.	1.4	12
27	Virtual screening, SAR, and discovery of $\epsilon$ -(indole-3-yl)- $\alpha$ -(2-((2-nitrophenyl)amino)[1,3,4]oxadiazole) as a novel Bcl-2 inhibitor. <i>Chemical Biology and Drug Design</i> , 2017, 90, 147-155.	3.2	33
28	Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents. <i>MedChemComm</i> , 2017, 8, 1414-1420.	3.4	2
29	Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. <i>British Journal of Cancer</i> , 2017, 117, 195-202.	6.4	6
30	Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1037-1040.	2.2	24
31	Fluorinated nucleosides as an important class of anticancer and antiviral agents. <i>Future Medicinal Chemistry</i> , 2017, 9, 1809-1833.	2.3	60
32	The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer. <i>Journal of Cancer</i> , 2016, 7, 2388-2407.	2.5	11
33	Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 230-243.	5.5	58
34	Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2030-2034.	2.2	44
35	ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5618-5623.	2.2	11
36	Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3636-3640.	2.2	16

#	ARTICLE	IF	CITATIONS
37	7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2000-2004.	2.2	23
38	Novel indole-based melatonin analogues substituted with triazole, thiadiazole and carbthioamides: studies on their antioxidant, chemopreventive and cytotoxic activities. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 1312-1321.	5.2	19
39	Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2016, 110, 311-325.	5.5	18
40	Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 745-757.	3.3	37
41	Abstract 3734: Preclinical evaluation of Rad6 inhibition to overcome platinum resistance in ovarian cancer. , 2016, , .		0
42	Fluorinated Pharmaceuticals: <i>Advances in Medicinal Chemistry</i> . , 2015, , .		10
43	Solidâ€Supported Iodonium Salts for Fluorinations. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 6909-6916.	2.4	15
44	Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells. <i>Biochemical Pharmacology</i> , 2015, 93, 332-342.	4.4	52
45	Convenient Synthesis of Diaryliodonium Salts for the Production of [ <sup>18</sup> F]Fâ€DOPA. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 625-630.	2.4	29
46	Synthesis of substituted carbamo(dithioperoxo)thioates as potential BCA2-inhibitory anticancer agents. <i>Tetrahedron Letters</i> , 2015, 56, 2583-2585.	1.4	9
47	Advances in small-molecule drug discovery for triple-negative breast cancer. <i>Future Medicinal Chemistry</i> , 2015, 7, 2019-2039.	2.3	14
48	Abstract 1662: Therapeutic relevance of the Rad6/translesion synthesis pathway in BRCA1-related triple-negative breast cancer cells. , 2015, , .		0
49	A novel radiochemical approach to 1-(2'-deoxy-2'-[ <sup>18</sup> F]fluoro-â€d-arabinofuranosyl)cytosine (18F-FAC). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 637-644.	1.0	6
50	Optimised synthesis of diamino-triazinylmethyl benzoates as inhibitors of Rad6B ubiquitin conjugating enzyme. <i>Tetrahedron Letters</i> , 2014, 55, 7015-7018.	1.4	8
51	Radiochemical synthesis of 2â€labelled and 3â€labelled nucleosides for positron emission tomography imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 333-337.	1.0	9
52	Synthesis, anti-HIV and cytostatic evaluation of 3â€deoxy-3â€fluorothymidine (FLT) pro-nucleotides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2240-2243.	2.2	6
53	Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2391-2394.	2.2	25
54	Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6886-6889.	2.2	26

#	ARTICLE	IF	CITATIONS
55	Synthesis and antioxidant properties of substituted 2-phenyl-1H-indoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2671-2674.	2.2	42
56	Convenient Synthesis of Substituted 2-Phenylbenzothiazoles Using Solid-Supported Triphenylphosphine. <i>Synthetic Communications</i> , 2013, 43, 2656-2662.	2.1	12
57	Medicinal chemistry: the academic perspective. <i>Future Medicinal Chemistry</i> , 2013, 5, 21-23.	2.3	0
58	Novel Inhibitors of Rad6 Ubiquitin Conjugating Enzyme: Design, Synthesis, Identification, and Functional Characterization. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 373-383.	4.1	52
59	Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.. <i>Current Medicinal Chemistry</i> , 2013, 20, 4451-4459.	2.4	41
60	The dark side of pharmaceutical chemistry. <i>Future Medicinal Chemistry</i> , 2012, 4, 129-132.	2.3	3
61	Synthesis and evaluation of indole-containing 3,5-diarylisoaxazoles as potential pro-apoptotic antitumour agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 56, 263-270.	5.5	23
62	An efficient synthetic route to biologically relevant 2-phenylbenzothiazoles substituted on the benzothiazole ring. <i>Tetrahedron</i> , 2011, 67, 7743-7747.	1.9	30
63	An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. <i>Tetrahedron</i> , 2011, 67, 9522-9528.	1.9	45
64	Ask the experts: future of the pharmaceutical industry. <i>Future Medicinal Chemistry</i> , 2011, 3, 1863-1872.	2.3	2
65	Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. <i>Free Radical Biology and Medicine</i> , 2010, 48, 98-111.	2.9	131
66	Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2200-2203.	2.2	25
67	Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 4523-4530.	5.5	45
68	Homology Modelling of Human E1 Ubiquitin Activating Enzyme. <i>Letters in Drug Design and Discovery</i> , 2010, 7, 57-62.	0.7	11
69	Exploring the Structural Requirements for Inhibition of the Ubiquitin E3 Ligase Breast Cancer Associated Protein 2 (BCA2) as a Treatment for Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2757-2765.	6.4	134
70	The role and future potential of fluorinated biomarkers in positron emission tomography. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 291-304.	5.0	14
71	Rapid and Convenient Thermal or Microwave-Assisted Synthesis of Substituted 2-Phenylbenzothiazoles. <i>Synthetic Communications</i> , 2010, 40, 3027-3032.	2.1	12
72	Structure-activity analysis of $\alpha$ -modified cinnamaldehyde analogues as potential anticancer agents. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 741-747.	2.1	22

#	ARTICLE	IF	CITATIONS
73	Synthesis and Biological Properties of Benzothiazole, Benzoxazole, and Chromen-4-one Analogues of the Potent Antitumor Agent 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5135-5139.	6.4	296
74	Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2008, 23, 641-647.	5.2	23
75	Protein-protein interactions as targets for small-molecule therapeutics in cancer. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e8.	3.9	92
76	2-[(1-Methylpropyl)dithio]-1-imidazole inhibits tubulin polymerization through cysteine oxidation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 143-151.	4.1	75
77	The Development of Pro-Apoptotic Cancer Therapeutics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 711-718.	2.4	14
78	Basal and angiotensin II-inhibited neuronal delayed-rectifier K <sup>+</sup> current are regulated by thioredoxin. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 293, C211-C217.	4.6	8
79	Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: How vanilloids cause non-vanilloid receptor mediated cell death. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 50-55.	2.1	88
80	Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 131-137.	2.1	119
81	Metabolically Stabilized Benzothiazoles for Imaging of Amyloid Plaques. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1087-1089.	6.4	74
82	Quinolins As Novel Therapeutic Agents. 7.1 Synthesis of Antitumor 4-[1-(Arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira Reactions. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1707-1710.	6.4	39
83	Novel antitumour agents: indanesulfonamides as selective inhibitors of the tumour-associated isozyme carbonic anhydrase IX. <i>Drug Discovery Today</i> , 2007, 12, 100.	6.4	1
84	Novel antitumour agents: antitumour activity of potent inhibitors of heat shock protein 90. <i>Drug Discovery Today</i> , 2007, 12, 101.	6.4	0
85	Selective targeting of DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. <i>Drug Discovery Today</i> , 2007, 12, 426-426.	6.4	0
86	The role of fluorine in medicinal chemistry. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2007, 22, 527-540.	5.2	540
87	Antitumor quinolins: Role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 242-251.	2.1	18
88	Structural Studies on Bioactive Compounds. 40.1 Synthesis and Biological Properties of Fluoro-, Methoxyl-, and Amino-Substituted 3-Phenyl-4H-1-benzopyran-4-ones and a Comparison of Their Antitumor Activities with the Activities of Related 2-Phenylbenzothiazoles. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3973-3981.	6.4	73
89	Structure of <i>Mycobacterium tuberculosis</i> thioredoxin C. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2006, 62, 1453-1457.	2.5	14
90	Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones (quinols <sup>TM</sup> ). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5005-5008.	2.2	103

#	ARTICLE	IF	CITATIONS
91	Antitumor Benzothiazoles. 26.12-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 179-185.	6.4	421
92	Inhibitors of the Hdm2:p53 complex as antitumour agents. <i>Drug Discovery Today</i> , 2006, 11, 371.	6.4	0
93	New aromatase inhibitors with potential in breast cancer treatment. <i>Drug Discovery Today</i> , 2006, 11, 1041.	6.4	1
94	Novel antitumour agents. <i>Drug Discovery Today</i> , 2006, 11, 1122-1123.	6.4	0
95	Antitubercular Properties of Substituted Hydroxycyclohexadienones. <i>Letters in Drug Design and Discovery</i> , 2006, 3, 419-423.	0.7	4
96	The war on cancer: an end in sight?. <i>Drug Discovery Today</i> , 2005, 10, 1082-1083.	6.4	0
97	Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer. <i>Current Cancer Drug Targets</i> , 2005, 5, 159-170.	1.6	57
98	Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols. <i>Cancer Research</i> , 2005, 65, 3911-3919.	0.9	79
99	Quinols as Novel Therapeutic Agents. 2.14-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and Related Agents as Potent and Selective Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 639-644.	6.4	53
100	Novel reaction products from the hypervalent iodine oxidation of hydroxylated stilbenes and isoflavones. <i>Organic and Biomolecular Chemistry</i> , 2005, 3, 3996.	2.8	17
101	Synthesis, Antitumor Evaluation, and Apoptosis-Inducing Activity of Hydroxylated (E)-Stilbenes. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1292-1295.	6.4	69
102	Advances in molecular targets and cancer therapeutics. <i>Drug Discovery Today</i> , 2004, 9, 207-209.	6.4	2
103	Hitting the chemotherapy jackpot: strategy, productivity and chemistry. <i>Drug Discovery Today</i> , 2004, 9, 625-627.	6.4	14
104	Molecular targets and cancer therapeutics. <i>Drug Discovery Today</i> , 2004, 9, 1042-1044.	6.4	0
105	A new era in cancer therapeutics?. <i>Drug Discovery Today</i> , 2003, 8, 64-65.	6.4	2
106	Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. <i>Biochemical Pharmacology</i> , 2003, 66, 1695-1705.	4.4	35
107	Antitumor Benzothiazoles. Part 20. 3- $\text{C}\equiv\text{N}$ -Cyano and 3- $\text{C}\equiv\text{N}$ -Alkynyl-Substituted 2-(4- $\text{NH}_2$ -Aminophenyl)benzothiazoles as New Potent and Selective Analogues.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
108	Antitumour benzothiazoles. Part 20: 3- $\text{C}\equiv\text{N}$ -Cyano and 3- $\text{C}\equiv\text{N}$ -Alkynyl-Substituted 2-(4- $\text{NH}_2$ -Aminophenyl)benzothiazoles as new potent and selective analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 471-474.	2.2	112

#	ARTICLE	IF	CITATIONS
109	4-Substituted 4-Hydroxycyclohexa-2,5-dien-1-ones with Selective Activities against Colon and Renal Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 532-541.	6.4	95
110	Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl)benzothiazoles to reactive intermediates by cytochrome P4501A1 Part 23. For part 22 see Ref. 1.. <i>Organic and Biomolecular Chemistry</i> , 2003, 1, 493-497.	2.8	56
111	Antitumor Benzothiazoles. 16.1 Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 744-747.	6.4	394
112	Monitor: molecules and profiles. <i>Drug Discovery Today</i> , 2002, 7, 148-150.	6.4	0
113	Novel telomerase inhibitors targeting quadreplex DNA; antitumour benzothiazoles; P-Glycoprotein efflux pump inhibitors; new topoisomerase inhibitors. <i>Drug Discovery Today</i> , 2002, 7, 528-531.	6.4	1
114	Antitumour Benzothiazoles. Part 15: The Synthesis and Physico-Chemical Properties of 2-(4-Aminophenyl)benzothiazole Sulfamate Salt Derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1093-1095.	2.2	32
115	Antitumor Benzothiazoles. 14.1 Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1446-1455.	6.4	332
116	Novel antitumour molecules. <i>Drug Discovery Today</i> , 2001, 6, 215-216.	6.4	0
117	Monitor: molecules and profiles. <i>Drug Discovery Today</i> , 2001, 6, 102-104.	6.4	2
118	Monitor: molecules and profiles. <i>Drug Discovery Today</i> , 2001, 6, 378-379.	6.4	0
119	Novel antitumour molecules. <i>Drug Discovery Today</i> , 2001, 6, 489-491.	6.4	2
120	Novel antitumour molecules. <i>Drug Discovery Today</i> , 2001, 6, 648-649.	6.4	0
121	Novel antitumour molecules. <i>Drug Discovery Today</i> , 2001, 6, 699-701.	6.4	2
122	Monitor and Molecules. <i>Drug Discovery Today</i> , 2001, 6, 1070-1071.	6.4	0
123	Monitor: molecules and profiles. <i>Drug Discovery Today</i> , 2001, 6, 1176-1177.	6.4	0
124	The regiospecific synthesis of 5- and 7-monosubstituted and 5,6-disubstituted 2-arylbenzothiazoles. <i>Tetrahedron Letters</i> , 2000, 41, 425-428.	1.4	79
125	Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 513-515.	2.2	92
126	Antitumor Benzothiazoles. 8.1 Synthesis, Metabolic Formation, and Biological Properties of the C- and N-Oxidation Products of Antitumor 2-(4-Aminophenyl)benzothiazoles. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4172-4184.	6.4	225



#	ARTICLE	IF	CITATIONS
127	Chapter 5 The chemistry of $\hat{1}\pm, \hat{1}^2$ -unsaturated sulfoxides. <i>Organosulfur Chemistry</i> , 1998, , 157-228.	0.5	7
128	Auxiliary accelerated reactions: Towards the use of catalytic chiral auxiliaries. <i>Tetrahedron</i> , 1997, 53, 13063-13078.	1.9	20
129	Auxiliary accelerated reactions: catalytic hydrogenation. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1996, , 1.	0.9	2
130	l-Azatyrosine: a new lead in anticancer drug development. <i>Drug Discovery Today</i> , 1996, 1, 401.	6.4	2
131	A concise synthesis of either enantiomer of azatyrosine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 2613-2616.	2.2	15
132	Homochiral 2,3-epoxy sulfidesâ€”powerful new synthetic building blocks providing stereoselective access to 2,3-epoxy sulfoxides, 2,3-dihydroxy sulfoxides and (E)- $\hat{1}^3$ -hydroxy- $\hat{1}\pm, \hat{1}^2$ -unsaturated sulfoxides and sulfones. X-Ray molecular structure of rac-(2R*,3R*)-1-[(S*)-phenylsulfinyl] hexane-2,3-diol. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1995, , 847-859.	0.9	26
133	Homochiral 2,3-epoxy sulfides as precursors to $\hat{1}^3$ -hydroxy- $\hat{1}\pm, \hat{1}^2$ -unsaturated sulfoxides and sulfones.. <i>Tetrahedron: Asymmetry</i> , 1994, 5, 355-358.	1.8	4
134	Auxiliary accelerated reactions: transition-metal promoted Dielsâ€”Alder cycloadditions. <i>Journal of the Chemical Society Chemical Communications</i> , 1994, , 2501-2502.	2.0	4
135	Stereoselective synthesis of 2,3-epoxy sulphoxides.. <i>Tetrahedron Letters</i> , 1992, 33, 7237-7240.	1.4	17
136	Lewis acid induced reaction of 2,3-epoxy phenylsulphoxides. <i>Tetrahedron Letters</i> , 1992, 33, 2409-2412.	1.4	13